Literature DB >> 24497563

Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up.

Giorgio Derchi1, Manuela Balocco, Patrizio Bina, Vincenzo Caruso, Domenico G D'Ascola, Roberto Littera, Raffaella Origa, Maria D Cappellini, Gian L Forni.   

Abstract

Entities:  

Keywords:  pulmonary hypertension; sildenafil; thalassemia

Mesh：

Substances：

Year:  2014        PMID： 24497563      PMCID： PMC3912977          DOI： 10.3324/haematol.2013.095810

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension.

Authors:  Roberto Littera; Giorgio La Nasa; Giorgio Derchi; Maria D Cappellini; Christy Y P Chang; Licinio Contu
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

Review 3.  Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked.

Authors:  Dimitrios Farmakis; Athanasios Aessopos
Journal:  Circulation       Date:  2011-03-22       Impact factor: 29.690

4.  Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies.

Authors:  Giorgio Derchi; Gian Luca Forni; Francesco Formisano; Maria Domenica Cappellini; Renzo Galanello; Giandomenico D'Ascola; Patrizio Bina; Carmelo Magnano; Martina Lamagna
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

5.  Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension.

Authors:  Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

6.  Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study.

Authors:  Giorgio Derchi; Renzo Galanello; Patrizio Bina; Maria Domenica Cappellini; Antonio Piga; Maria-Eliana Lai; Antonella Quarta; Gavino Casu; Silverio Perrotta; Valeria Pinto; Khaled M Musallam; Gian Luca Forni
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

7.  Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.

Authors:  A Sebkhi; Julian W Strange; Steven C Phillips; John Wharton; Martin R Wilkins
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690
  7 in total
  3 in total

1.  Response to "efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " Haematologica 2014;99(2):e17-18.

Authors:  Elizabeth S Klings; Elliott P Vichinsky; Claudia R Morris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

2.  Pulmonary hypertension in thalassemia: a call to action.

Authors:  John C Wood
Journal:  Blood       Date:  2022-03-31       Impact factor: 22.113

Review 3.  Sickle cell disease: a review for the internist.

Authors:  Valeria Maria Pinto; Manuela Balocco; Sabrina Quintino; Gian Luca Forni
Journal:  Intern Emerg Med       Date:  2019-08-05       Impact factor: 5.472
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.